Scilex Holding Co
SCLX
View Detailed Chart
8.490USD
+0.630+8.02%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
52.02MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+8.02%
5 Days
-0.35%
1 Month
-35.19%
6 Months
-43.06%
Year to Date
-30.41%
1 Year
-33.80%
View Detailed Chart
TradingKey Stock Score of Scilex Holding Co
Currency: USD Updated: 2026-02-06Key Insights
Scilex Holding Co's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 117 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 490.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Scilex Holding Co's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Scilex Holding Co Highlights
StrengthsRisks
Scilex Holding Company is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 48.79% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 56.59M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 56.59M.
Overvalued
The company’s latest PE is -0.27, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.24M shares, increasing 17.42% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 295.02K shares of this stock.
Analyst Rating
Based on
1
analysts
Hold
Current Rating
490.000
Target Price
+3319.40%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Scilex Holding Co News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Scilex Holding Co Info
Scilex Holding Company is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
Ticker SymbolSCLX
CompanyScilex Holding Co
CEOJi (Henry H)
Websitehttps://www.scilexholding.com/
Related Instruments
+3.66%
+3.14%
+0.93%
+2.01%
+1.82%
+1.60%
-0.95%
+4.49%
+2.10%
+9.92%
+2.76%
+4.15%
+1.79%
+4.17%
+0.72%
+1.10%
+2.46%
0.00%
+0.51%
+0.54%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68676.000
-1294.130 (-1.85%)
282.580
+22.390 (+8.61%)
2026.200
-25.530 (-1.24%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
